Administration of anti-HER2 and satisfaction of patients treated for breast cancer
Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: Quality of life (QoL) and patient satisfaction are major concerns in oncology.
METHODS: The aim of this prospective observational study was to evaluate these parameters according to the mode of administration of anti-HER2 (subcutaneous [SC] versus intravenous [IV]), the place of administration (Home Hospitalization or HOD versus hospital) for patients supervised by an advanced practice nurse (APN).
RESULTS: Between January 2022 and June 2023, 32 patients were included. They were statistically more satisfied with subcutaneous management (P=0.0004), a result explained by the speed of administration (43.5%), comfort during administration (26%) even though some expressed pain on injection and felt less anxiety (26%). Management by the APN seems more appropriate when anti-HER2 drugs were administered in HOD. In HOD, patients perceived an overall improvement in their quality of life, appetite and cognitive abilities, with a reduction in fatigue, pain and depression (P<0.05). However, the rate of outsourcing to HOD remained too low (30.4%), as 56.3% of patients would have liked to be cared for in HOD if they had had the opportunity.
CONCLUSION: SC administration of anti-HER2 under the supervision of an APN has advantages for the patient, resulting in greatest satisfaction and improved patient QOL, preferably in HOD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Bulletin du cancer - (2024) vom: 12. März |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Administration des anti-HER2 et satisfaction des patients avec un cancer du sein |
|---|
| Beteiligte Personen: |
Pallaro, Solène [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.bulcan.2024.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369697634 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369697634 | ||
| 003 | DE-627 | ||
| 005 | 20240315000316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2024.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369697634 | ||
| 035 | |a (NLM)38480056 | ||
| 035 | |a (PII)S0007-4551(24)00074-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Pallaro, Solène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Administration of anti-HER2 and satisfaction of patients treated for breast cancer |
| 246 | 3 | 3 | |a Administration des anti-HER2 et satisfaction des patients avec un cancer du sein |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: Quality of life (QoL) and patient satisfaction are major concerns in oncology | ||
| 520 | |a METHODS: The aim of this prospective observational study was to evaluate these parameters according to the mode of administration of anti-HER2 (subcutaneous [SC] versus intravenous [IV]), the place of administration (Home Hospitalization or HOD versus hospital) for patients supervised by an advanced practice nurse (APN) | ||
| 520 | |a RESULTS: Between January 2022 and June 2023, 32 patients were included. They were statistically more satisfied with subcutaneous management (P=0.0004), a result explained by the speed of administration (43.5%), comfort during administration (26%) even though some expressed pain on injection and felt less anxiety (26%). Management by the APN seems more appropriate when anti-HER2 drugs were administered in HOD. In HOD, patients perceived an overall improvement in their quality of life, appetite and cognitive abilities, with a reduction in fatigue, pain and depression (P<0.05). However, the rate of outsourcing to HOD remained too low (30.4%), as 56.3% of patients would have liked to be cared for in HOD if they had had the opportunity | ||
| 520 | |a CONCLUSION: SC administration of anti-HER2 under the supervision of an APN has advantages for the patient, resulting in greatest satisfaction and improved patient QOL, preferably in HOD | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Administration sous-cutanée | |
| 650 | 4 | |a Advanced practice nursing | |
| 650 | 4 | |a Anti-HER2 treatment | |
| 650 | 4 | |a Home hospitalization | |
| 650 | 4 | |a Hospitalisation à domicile | |
| 650 | 4 | |a Infirmière de pratique avancée | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Qualité de vie | |
| 650 | 4 | |a Subcutaneous administration | |
| 650 | 4 | |a Traitement anti-HER2 | |
| 700 | 1 | |a Bigas, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Leobon, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Baffert, Kim-Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Peyramaure, Clémentine |e verfasserin |4 aut | |
| 700 | 1 | |a Dubest, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Venat, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Maillan, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Deluche, Élise |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g (2024) vom: 12. März |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2024.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 03 | ||